Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.
D000726:Androgen Antagonists / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D011389:Prolactin Release-Inhibiting Factors / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000008:administration & dosage; D017329:Triptorelin Pamoate
D000726:Androgen Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; D011389:Prolactin Release-Inhibiting Factors